Ascentage Pharma Group International (AAPG) Competitors $38.88 -0.98 (-2.46%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AAPG vs. ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, VRNA, and RVMDShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Ascentage Pharma Group International (NASDAQ:AAPG) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Do analysts recommend AAPG or ASND? Ascendis Pharma A/S has a consensus target price of $244.36, suggesting a potential upside of 16.44%. Given Ascendis Pharma A/S's higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is AAPG or ASND more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group InternationalN/A N/A N/A Ascendis Pharma A/S -54.94%N/A -24.31% Does the media refer more to AAPG or ASND? In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 3 mentions for Ascendis Pharma A/S and 2 mentions for Ascentage Pharma Group International. Ascendis Pharma A/S's average media sentiment score of 0.32 beat Ascentage Pharma Group International's score of 0.25 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, AAPG or ASND? Ascentage Pharma Group International has higher earnings, but lower revenue than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscentage Pharma Group International$134.35M26.96-$55.54MN/AN/AAscendis Pharma A/S$393.54M32.90-$409.12M-$5.16-40.67 SummaryAscendis Pharma A/S beats Ascentage Pharma Group International on 6 of the 10 factors compared between the two stocks. Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.71B$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.69%4.74%P/E RatioN/A21.4185.6126.85Price / Sales26.96466.25612.81135.13Price / CashN/A47.6737.7861.77Price / Book81.0010.0613.256.70Net Income-$55.54M-$52.22M$3.30B$276.44M7 Day Performance-0.41%5.84%4.70%3.13%1 Month Performance-4.00%12.05%8.43%10.21%1 Year PerformanceN/A26.13%88.01%40.35% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$38.88-2.5%N/AN/A$3.71B$134.35M0.00600News CoverageASNDAscendis Pharma A/S3.0303 of 5 stars$204.05+1.5%$244.36+19.8%+47.8%$12.57B$393.54M-39.541,017VTRSViatris1.7687 of 5 stars$10.19+0.8%$10.40+2.1%-12.6%$11.88B$14.74B-3.5132,000RDYDr. Reddy's Laboratories3.2866 of 5 stars$14.17+0.7%$16.95+19.7%-9.8%$11.82B$3.81B21.4627,811Positive NewsMRNAModerna4.3151 of 5 stars$28.49+0.4%$41.81+46.8%-54.3%$11.08B$3.24B-3.785,800ROIVRoivant Sciences3.4967 of 5 stars$16.17+1.2%$19.94+23.3%+42.9%$11.04B$29.05M0.00860QGENQIAGEN4.4517 of 5 stars$46.83+1.3%$49.40+5.5%+10.9%$10.40B$1.98B27.675,765ELANElanco Animal Health2.6896 of 5 stars$20.65+0.9%$18.33-11.2%+41.1%$10.25B$4.44B24.019,000News CoverageAnalyst UpgradeBBIOBridgeBio Pharma4.2734 of 5 stars$52.86-0.8%$63.94+21.0%+116.4%$10.11B$221.90M-12.92400VRNAVerona Pharma PLC American Depositary Share1.9933 of 5 stars$106.790.0%$109.00+2.1%+234.0%$9.20B$42.28M-107.8730Positive NewsRVMDRevolution Medicines4.2767 of 5 stars$46.71+2.2%$74.64+59.8%-1.6%$8.73B$11.58M-10.38250 Related Companies and Tools Related Companies ASND Alternatives VTRS Alternatives RDY Alternatives MRNA Alternatives ROIV Alternatives QGEN Alternatives ELAN Alternatives BBIO Alternatives VRNA Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
